Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.34 |
| ▸ | KDM6B | O15054 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18857757 | 0.94 | KDM4C (0.36) | ECE1MUS81KDM4CKDM6B | |
| SCHEMBL18857759 | 0.92 | ECE1 (0.34) | ECE1MUS81KDM4CKDM6BCA12 | |
| SCHEMBL18857760 | 0.86 | KDM4C (0.34) | ECE1MUS81KDM4CKDM6BCA12 | |
| SCHEMBL18857746 | 0.71 | KDM4C (0.43) | ECE1MUS81KDM4CKDM6BCA12 | |
| SCHEMBL18857751 | 0.70 | HPGD (0.40) | KDM4CKDM6BCA12CA1CA2 | |
| SCHEMBL18857747 | 0.67 | KDM4C (0.46) | KDM4CKDM6BCA12CA1CA2 | |
| SCHEMBL3068769 | 0.67 | KDM4C (0.57) | ECE1MUS81KDM4CKDM6B | |
| SCHEMBL14576594 | 0.63 | PTGER4 (0.46) | KDM4CKDM6B | |
| SCHEMBL18857755 | 0.63 | HPGD (0.44) | KDM4CKDM6BCA12CA1CA2 | |
| SCHEMBL20182718 | 0.62 | KDM4E (0.31) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180134662-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges Antibiotics and Myelin Disease Therapy | TPAT IP LLC | 2018-05-17 | — | — | US | disclosed |
| US-9867813-B2 | Aminopyridine based buffers with wide buffering ranges, antibiotics and myelin disease therapy | TPAT IP LLC | 2018-01-16 | — | — | US | disclosed |
| US-20170135998-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy | TPAT IP LLC | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134662-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges Antibiotics and Myelin Disease Therapy | AQP4, PMP22, MAG | ECE1 2779/4885MUS81 3005/4885KDM4C 2547/4885 |
| US-20170135998-A1 | Aminopyridine Based Buffers with Wide Buffering Ranges, Antibiotics and Myelin Disease Therapy | AQP4, PMP22, MAG | ECE1 2720/4885MUS81 3040/4885KDM4C 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.